The *VPS13C* gene is located within a risk locus for Parkinson disease (PD), reported in large genome-wide association studies (GWASs) of European population.^[@R1],[@R2]^ The single nucleotide polymorphism (SNP) reported in the GWAS (rs2414739, chr15.hg19:g.61994134G\>A) was also studied in several Asian populations and in Iranians, with conflicting results,^[@R3][@R4][@R7]^ possibly because of ethnicity-related differences.

Subsequently, homozygous and compound heterozygous *VPS13C* mutations were identified as a rare cause of early onset PD (EOPD) characterized by rapid progression and early cognitive dysfunction. It was demonstrated that *VPS13C* is partially localized at the mitochondrial membrane, and its silencing led to mitochondrial dysfunction and increased PINK1/Parkin-dependent mitophagy.^[@R8]^ A follow-up study in 80 patients with EOPD identified an additional patient with compound heterozygous mutations with similar clinical features to the previously reported patients.^[@R9]^ In another recent study, a homozygous deletion in *VPS13C* was reported to be the probable cause of early onset parkinsonism in 1 patient.^[@R10]^ Thus far, full sequencing studies of *VPS13C* have not been reported in late-onset PD (LOPD).

To further study the potential role of *VPS13C* variants in PD, we sequenced its coding and regulatory regions using targeted next-generation sequencing in 3 cohorts of PD (predominantly LOPD) and in controls. We examined the association of common, rare, and biallelic *VPS13C* variants on the risk for PD. We further tested whether any coding variant or variants in the untranslated regions of *VPS13C* are in linkage disequilibrium (LD) with the top *VPS13C*-associated GWAS hit to determine if any of these variants can explain the GWAS association of this locus.

Methods {#s1}
=======

Study population {#s1-1}
----------------

Three cohorts, with a total of 1,567 unrelated patients with PD and 1,667 controls, were included in this study, detailed in [table 1](#T1){ref-type="table"}. The first cohort was composed of French and French Canadian participants recruited in Quebec (Canada) and in France. This cohort was previously genotyped using the GWAS OmniExpress array, the ethnicity was confirmed using principal component analysis, and the samples that were of different ethnicities were not included in this study. The second cohort was recruited in New York---Columbia University and was previously described.^[@R11]^ Most participants from New York are of European descent and 38% are Ashkenazi Jewish (AJ), 40% of patients with PD, and 35% of controls. This difference was not statistically significant, yet we adjusted for ethnicity when analyzing this cohort to avoid effects of ethnicity on the results. The third cohort was recruited in Israel (Sheba Medical Center), and all participants included in this study from the Israeli cohort are of full AJ origin (all 4 grandparents are full AJ). All patients were consecutively recruited through the clinics, and they represent the typical LOPD patient population with age at onset (AAO) of about 60 ([table 1](#T1){ref-type="table"}), as opposed to the studies published so far on *VPS13C* in EOPD. As detailed below, because of the differences in age and sex ([table 1](#T1){ref-type="table"}), statistical analysis was adjusted and included age and sex as covariates. To account for different ethnicities in the New York cohort, an ethnicity covariate was also introduced in this cohort (GWAS data were not available for this cohort; therefore, the reported ethnicity was used and not principal components). All 3 cohorts were sequenced in the same laboratory (McGill University), following the same protocol. All patients with PD were diagnosed by movement disorder specialists according to the UK Brain Bank criteria,^[@R12]^ without excluding patients with family history of PD, because it is now known that there are familial cases of PD, so patients who reported family history of PD were included. However, it is important to emphasize that in the current study, only unrelated patients were included and there were no multiple cases from the same family.

###### 

Study population details

![](NG2019011510t1)

Standard protocol approvals, registrations, and patient consents {#s1-2}
----------------------------------------------------------------

The institutional review board (McGill University Health Center Research Ethics Board---MUHC REB) approved the study protocols (reference number IRB00010120). Informed consent was obtained from all individual participants before entering the study.

DNA extraction and *VPS13C* sequencing {#s1-3}
--------------------------------------

DNA was extracted using a standard salting out protocol. The coding sequence and regulatory regions of *VPS13C* were targeted using molecular inversion probes (MIPs), which were designed as previously described.^[@R13]^ MIPs were selected based on their predicted coverage, quality, and overlap. All MIPs used to sequence *VPS13C* in the present study are included in table e-1, [links.lww.com/NXG/A205](http://links.lww.com/NXG/A205). Targeted DNA capture and amplification was performed as previously described,^[@R14]^ and the full protocol is available on request. The library was sequenced using an Illumina HiSeq 2,500 platform at the McGill University and Genome Quebec Innovation Centre. Reads were mapped to the human reference genome (hg19) with Burrows-Wheeler Aligner.^[@R15]^ Genome Analysis Toolkit (v3.8) was used for postalignment quality control (QC) and variant calling,^[@R16]^ and annotation variation was used for annotation.^[@R17]^ Data on the frequency of each *VPS13C* variant were extracted from the public database Genome Aggregation Database (GnomAD).^[@R18]^ Validation of the tagging variant p.I1132V was performed using Sanger sequencing, with the following primers: forward 5′-CCGGGAAGGTAATGACAAAA-3′ and reverse 5′-CCCCTGATTGAAAAGTCACA-3′.

Quality control {#s1-4}
---------------

During QC filtration using PLINK software v1.9,^[@R19]^ SNPs with genotyping rate lower than 90% were excluded. Genotyping rate cut-off for individuals was 90%, and individuals with a lower genotyping rate were excluded. SNPs that deviated from Hardy-Weinberg equilibrium set at *p* = 0.001 threshold were filtered out. Threshold for missingness difference between cases and controls was set at *p* = 0.05 and the filtration script adjusted it with Bonferroni correction. After these QC steps, cohort composition was as described in [table 1](#T1){ref-type="table"}. To be included in the analysis, minimum quality score (GQ) was set to 30. Rare variants (minor allele frequency \[MAF\] \<0.01 or 0.001) had to have a minimal coverage of \>50× to be included, and common variants had to have a minimal coverage of \>15× to be included in the analysis.

Statistical analysis {#s1-5}
--------------------

The association between common *VPS13C* variants and PD was examined by using logistic regression models using PLINK v1.9, with the status (patient or control) as a dependent variable, age and sex as covariates in all cohorts, and AJ ancestry as an additional covariate in the New York cohort. To analyze rare variants (MAF \<0.01) and very rare variants (MAF \<0.001), an optimized sequence kernel association test (SKAT-O, R package) was performed.^[@R20]^ In addition, we examined the burden of predicted pathogenic variants using SKAT-O with Combined Annotation Dependent Depletion (CADD) score of ≥12.37 representing the top 2% of potentially deleterious variants. The effects of SNP genotypes on the AAO was tested using analysis of variance (ANOVA; in R software). Meta-analysis of common variants in the 3 cohorts was performed using metafor package in R software.^[@R21]^ LD in our data were examined by PLINK v1.9 and LD between discovered SNPs and the GWAS top hit rs2414739 was tested using LDlink application, selecting all non-Finish Europeans.^[@R22]^

Data availability {#s1-6}
-----------------

Anonymized data are available on request by any qualified investigator.

Results {#s2}
=======

Rare *VPS13C* variants and homozygous or compound heterozygous *VPS13C* variants are not associated with LOPD {#s2-1}
-------------------------------------------------------------------------------------------------------------

The average coverage of *VPS13C* with the MIPs was 94% of nucleotides covered at \>10× and 90% covered at \>50×. This coverage, while not ideal, is better than the whole exome sequencing coverage reported in the original study on *VPS13C* in PD and better than the whole exome and whole genome sequencing coverage of this specific gene in GnomAD ([gnomad.broadinstitute.org/](https://gnomad.broadinstitute.org/)). There were no differences in coverage between the cohorts and between patients and controls. A total of 60 rare variants that are nonsynonymous, stop variants, or potentially affect a splicing site were identified in the 3 cohorts and are detailed in table e-2, [links.lww.com/NXG/A206](http://links.lww.com/NXG/A206).

To examine whether rare homozygous or compound heterozygous *VPS13C* variants may cause LOPD, and because patients with *VPS13C* biallelic mutations are very rare, we included only rare variants with allele frequency \<0.001 in this analysis. Only 2 carriers of 2 heterozygous variants were identified, and both were controls (table e-3, [links.lww.com/NXG/A207](http://links.lww.com/NXG/A207)), suggesting that biallelic mutations are not common in LOPD. Of note, we did not examine whether these 2 variants were on the same allele or different allele (compound heterozygous) because they were found only in controls, which suggests that rare biallelic variants are not involved in LOPD in our cohorts.

To further study a potential role for rare (allele frequency \<0.01) or very rare (allele frequency \<0.001) *VPS13C* nonsynonymous or splice variants in LOPD, a SKAT-O was performed on the variants detailed in table e-2, [links.lww.com/NXG/A206](http://links.lww.com/NXG/A206). In the French and French Canadian cohort, 33 (6.6%) patients with PD carried a rare variant compared with 49 (6.2%) in controls. In the NY cohort, 43 patients with PD (8.6%) carried a rare variant compared with 29 (11.8%) in controls. In the Israeli cohort, 57 (11.9%) patients with PD carried a rare variant compared with 59 (12.1%) among controls. There was no association between rare variants (French/French Canadian cohort *p* = 0.44, New York cohort *p* = 0.34, and Israel cohort *p* = 0.91) or very rare variants (French/French Canadian cohort *p* = 0.17, New York cohort *p* = 0.85, and Israel cohort *p* = 0.89) and PD. We further examined whether rare variants that are predicted to be deleterious based on CADD score ≥12.37 are enriched in PD (the variants included in this analysis are detailed in table e-4, [links.lww.com/NXG/A208](http://links.lww.com/NXG/A208)), and no association was found (French/French Canadian cohort *p* = 0.58, New York cohort *p* = 0.39, and Israel cohort *p* = 0.40).

A *VPS13C* haplotype including the p.R153H-p.I398I-p.I1132V-p.Q2376Q coding variants is nominally associated with reduced risk for PD {#s2-2}
-------------------------------------------------------------------------------------------------------------------------------------

We have identified 14 common coding variants in our cohort of French and French Canadians and 13 such variants in each of the NY and Israeli cohorts. More details on the number of carriers and frequencies can be found in table e-5, [links.lww.com/NXG/A209](http://links.lww.com/NXG/A209). To test whether common coding variants in *VPS13C* are associated with LOPD, logistic regression models adjusted for age and sex were performed and additional adjustment for ethnicity was included in the New York cohort (see methods). A nominal association was observed in 4 variants (p.R153H \[rs12595158, chr15.hg19:g.62316035C\>T\], p.I398I \[rs9635356, chr15.hg19:g.62299603T\>G\], p.I1132V \[rs3784635, chr15.hg19: g.62254989T\>C\], and p.Q2376Q \[rs17238189, chr15.hg19: g.62212781T\>C\]) with reduced risk for PD in the New York cohort ([table 2](#T2){ref-type="table"}). These remained nominally significant with and without including adjustment for ethnicity, suggesting that ethnicity has no role in this association and only one of them, p. I1132V (odds ratio 0.28, 95% confidence interval 0.12--0.64, *p* = 0.0025), remained statistically significant after correction for multiple comparisons. In the 2 other cohorts, these variants showed the same directionality as in the New York cohort but did not reach statistical significance ([table 2](#T2){ref-type="table"}). These 4 variants, p.R153H, p.I398I, p.I1132V, and p.Q2376Q, are in strong or even complete LD (table e-6, [links.lww.com/NXG/A210](http://links.lww.com/NXG/A210)). The most significant tagging SNP of this haplotype, p. I1132V, was validated using Sanger sequencing in all 3 cohorts. Meta-analysis of all the common coding variants showed an association of these 4 linked SNPs with reduced risk for PD ([figure](#F1){ref-type="fig"}), with similar directionality across all cohorts. To examine whether this haplotype may affect AAO of PD, ANOVA with the status of the p. I1132V variant was performed. This variant was not associated with AAO in all 3 cohorts (French/French Canadian cohort *p* = 0.65, New York cohort *p* = 0.34, and Israel cohort *p* = 0.99).

###### 

Four variants forming the protective haplotype found in *VPS13C* and the results of the logistic regression in 3 cohorts
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![Forest plots---meta-analyses of 4 VPS13C coding variants associated with reduced risk for PD\
The forest plots depict the effects of the 4 *VPS13C* coding variants that create the haplotype associated with reduced PD risk in the 3 cohorts studied and their meta-analyzed effect on risk for PD. The results in the random effect model are nearly identical. CI = confidence interval; FE = fixed effect; PD = Parkinson disease.](NG2019011510f1){#F1}

None of these variants were in LD with the known GWAS top hit, rs2414739, and therefore, these associations do not explain the GWAS hit in the *VPS13C* locus. Of all the other common coding variants, only one variant, p.E2008D (rs78071599, chr15.hg19: g.62223303C\>G), was in some LD with the GWAS top hit (D\' = 0.808, r^2^ = 0.006, table e-7, [links.lww.com/NXG/A211](http://links.lww.com/NXG/A211)), but this variant was not associated with LOPD, and therefore, it also cannot explain the GWAS hit in our populations. Of interest, an intronic variant, rs78530361 (chr15.hg19: g.62214265C\>T), was in LD with the top GWAS SNP (D\' = 1, r^2^ = 0.003). Of note, r^2^ is low since this intronic SNP has a much lower allele frequency than the top GWAS hit, but every time the rs78530361 SNP is found, it is on an allele which harbors the top GWAS hit rs2414739. However, in our cohorts, this variant was not associated with PD (*p* = 0.66), likely because of its very low r^2^ with the GWAS hit.

Discussion {#s3}
==========

Our study, which included full sequencing of *VPS13C* in 3 cohorts, identified 60 rare *VPS13C* variants (MAF \<0.01) that are nonsynonymous or affect splicing and 18 common variants (MAF \>0.01) in coding regions of the gene and splice sites. Our results suggest that rare homozygous and compound heterozygous variants are rare in LOPD and probably have importance mainly in EOPD, as previously described. We have identified a potentially protective haplotype, which includes 4 variants, 2 of which are substitutions of amino acids, p.R153H and p.I1132V. The association was mainly driven by the NY cohort, but the 2 other cohorts demonstrated similar directionality of effect and effect size and also contributed to the association. It is unlikely that differences in ethnicity in the NY cohort drove the association because analysis was with adjustment for ethnicity and analysis without adjustment yielded nearly identical results, ruling out the effect of ethnicity. The other 2 cohorts were of homogeneous ethnicities; therefore, in these cohorts too, ethnicity could not have affected the results. Of interest, this haplotype is not in LD with the top GWAS SNP, rs2414739, suggesting that this may be a secondary association in the *VPS13C* locus, which was not identified in the previous studies. However, this should be considered as preliminary results and needs to be examined in additional cohorts to conclude whether this haplotype is indeed associated with reduced risk for PD. Because the disease-causing mutations reported in *VPS13C* are loss-of-function mutations, a protective effect could occur, for example, because of the gain of function or overexpression. In GTEx ([gtexportal.org/home/](https://www.gtexportal.org/home/)), these variants were not associated with increased expression or affect splicing. The 2 nonsynonymous variants of this haplotype, p.R153H and p.I1132V, have high CADD scores (22.8 and 13.7, respectively), suggesting that they may affect the protein structure or function. Whether there is such effect and whether it is associated with gain-of-function mutation will need to be examined in follow-up studies. Furthermore, the full sequencing analysis did not identify any coding variant that is in LD, with the original GWAS hit that can explain the GWAS association in this locus. This may suggest that the variant that has the main effect on the risk for PD in the *VPS13C* is outside of the coding and untranslated regions of the gene, likely being a regulatory element.

Previous studies on the top GWAS hit in the *VPS13C* locus demonstrated conflicting results. Although significant associations of the top GWAS hit in this locus (rs2414739) with PD were found in Iranian^[@R5]^ and East Asian^[@R3]^ populations, negative results were reported in Taiwanese^[@R4]^ and Han Chinese^[@R6],[@R7]^ populations. Therefore, it is possible that the association of *VPS13C* with PD is population dependent. Of note, the association in the current study was mainly driven by populations enriched in Ashkenazi Jews, whereas in the French/French Canadian cohort, the differences between patients and controls were much smaller and not statistically significant ([table 2](#T2){ref-type="table"}). This may suggest that this haplotype association is population specific, and additional studies in different populations are required to answer this question.

In our 3 cohorts, we did not find any very rare homozygous variants with MAF \<0.001 and found only 2 carriers of 2 heterozygous variants, both of which were controls (table e-3, [links.lww.com/NXG/A207](http://links.lww.com/NXG/A207)). We were unable to determine if the variants were in cis or trans, but because no carriers of 2 variants were found among patients, it is clear that *VPS13C* biallelic mutations do not contribute to PD in our cohorts. Previously reported cases of PD in carriers of compound heterozygous or homozygous mutations, all shared a specific clinical presentation of PD: early onset, rapid progression, and early cognitive dysfunction.^[@R8],[@R9]^ In 1 study, the patient\'s AAO was 39 and disease progression was moderately severe with psychiatric symptoms and impaired cognition.^[@R9]^ In another study, the 3 patients showed severe phenotypes: AAO of 25, 33, and 46 years, severe and early cognitive dysfunction, and became bedridden at 31, 43, and 58 years, respectively. Considering the young age of one of the compound heterozygous *VPS13C* variant carriers in our cohort (30 years), it is still possible although unlikely that this individual will develop PD in the future. The negative results of the SKAT-O analyses demonstrate that rare heterozygous variants in *VPS13C* do not have an important role in PD in our cohorts.

Our study has several limitations. The differences between patients with PD and controls in sex and mainly age are significant in some of our cohorts. To address this limitation, we included age and sex as covariates in the regression models. Therefore, if the association of the protective haplotype was related to age and not to disease status, we would likely not observe an association in the adjusted model. Furthermore, the association with the haplotype had the same directionality and similar effect size in the NY cohort in which the controls were older (and the association was statistically significant), and in the other 2 cohorts, where the controls were younger, likely ruling out the effect of age. There was no significant difference in the percentage of Ashkenazi Jews between patients and controls in the New York cohort, yet we still performed the regression model with and without ethnicity as a covariate, and in both analyses, the results remained significant. Nevertheless, the fact that our populations are enriched with relatively homogeneous populations such as Ashkenazi Jews and French Canadians requires additional studies in other populations. Another potential limitation is that we could not analyze the effect of CNVs in *VPS13C* with our data. Loss of function and exonic deletions/duplications are rare in gnomAD, found in only 3 individuals at a heterozygous state, and therefore not likely to have a major contribution in PD. However, future studies to examine the potential role of *VPS13C* in PD are required. Furthermore, because no functional experiments were performed in the current study, the potential effects of variants that we report here should be examined in additional studies.

In conclusion, our results suggest that *VPS13C* variants have a limited role in late-onset PD. The potentially PD protective haplotype located within *VPS13C,* which requires additional replications, may suggest that *VPS13C* could be a future target for PD therapeutic development. If naturally occurring genetic variants may reduce PD risk, it is conceivable that drugs that can mimic their effects could be developed. Additional genetic and functional studies will be required to determine if *VPS13C* may be a viable target for PD drug development.
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